• PeepinGoodArgs@reddthat.com
    link
    fedilink
    English
    arrow-up
    19
    ·
    1 year ago

    Honestly, this makes me beyond happy. I’m really hoping Lina Khan comes through with some huge wins that break up big tech.

  • QHC@lemmy.one
    link
    fedilink
    arrow-up
    16
    ·
    edit-2
    1 year ago

    Very interesting read.! Always eye-opening to get the perspective of someone that is so focused on a specific angle. Like so many things lately, this takeaway at the end is both encouraging and simultaneously terrifying:

    The irony of this remarkable month of antitrust activity is that it’s both astonishing, far more bigger [sic] than anything anyone expected, yet it’s also only a tiny fraction of what is necessary to reverse the damage monopolists have done to our society.

    (emphasis added)

    • tintory@lemm.eeOP
      link
      fedilink
      arrow-up
      4
      arrow-down
      1
      ·
      1 year ago

      I love posting stuff from guys like these, it always a treat to see people’s reactions to their stuff

  • ArtVandelay@lemmy.world
    link
    fedilink
    English
    arrow-up
    7
    ·
    1 year ago

    Makes sense to me, as the big companies approach enshittification at the same time, the inevitable pushback against them arrive near the same time as well.

  • AutoTL;DR@lemmings.worldB
    link
    fedilink
    English
    arrow-up
    3
    arrow-down
    1
    ·
    1 year ago

    This is the best summary I could come up with:


    There is also smaller stuff, the behind-the-scenes institutional changes, like funding levels for antitrust enforcers and newly populist conservative nominees for regulatory agencies that could make a more assertive competition agenda part of a new bipartisan consensus.

    The trial has generally gone well for the government, with good evidence that Google thwarted competition from small firms (Branch Technologies) and big ones (Microsoft and Apple), using payoffs.

    September 14: The Federal Trade Commission pledged criminal referrals and civil litigation for pharmaceutical executives that use a certain technique - known as ‘Orange Book fraud’ to lie about their patents and in turn block lower priced drugs.

    September 21: The Federal Trade Commission, with votes from Commissioners Alvaro Bedoya, Becca Kelly Slaughter, and Lina Khan, sued a New York private equity firm and its subsidiary, U.S. Anesthesia Partners, for rolling up and monopolizing the anesthesiology market in Texas.

    September 28: The Antitrust Division sues over meat price-fixing in the chicken, turkey, and poultry industry, alleging that 90% of the market is unlawfully inflated through a conspiracy run by a company called Agri Stats.

    This one didn’t get a lot of notice, but it’s about a way that CVS Caremark, one of the largest pharmaceutical middlemen, ends up harming independent pharmacies by charging them excess and unpredictable fees involving Medicare prescription dispensing.


    The original article contains 2,322 words, the summary contains 218 words. Saved 91%. I’m a bot and I’m open source!